Arch. Endocrinol. Metab. 2022;66(4):587

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

DOI: 10.20945/2359-3997000000520

DOI: 10.20945/2359-3997000000451

Arch Endocrinol Metab. 2022;66(2):269-71

[…]

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

Comments (0)